Clinical Course and Side Effects of Anti-IgE Monoclonal Antibody in Patients with Severe Persistent Asthma


Yalcin A. D. , Bisgin A. , Cetinkaya R., Yildirim M., Gorczynski R. M.

CLINICAL LABORATORY, vol.59, pp.71-77, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59
  • Publication Date: 2013
  • Doi Number: 10.7754/clin.lab.2012.120406
  • Title of Journal : CLINICAL LABORATORY
  • Page Numbers: pp.71-77

Abstract

Background: Omalizumab, a recombinant humanized monoclonal antibody to IgE, is recommended as a new option for the treatment of severe persistent allergic asthma. The purpose of this study is to assess the effects omalizumab treatment on life quality and its side effects in severe persistent asthma patients.